ReviewThe Journal of antimicrobial chemotherapy2009
Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects.
Review in The Journal of antimicrobial chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers.The Cochrane database of systematic reviews · 2017Pooled it
- Chlorhexidine and Mupirocin for Clearance of Methicillin-Resistant Staphylococcus aureus Colonization After Hospital Discharge: A Secondary Analysis of the Changing Lives by Eradicating Antibiotic Resistance Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Trial
- Increase in imported mupirocin-resistantNew microbes and new infections · 2026Article
- Staphylococcus aureus colonisation and strategies for decolonisation.The Lancet. Microbe · 2024Review
- In Vitro and Ex Vivo Investigation of the Antibacterial Effects of Methylene Blue against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Identification of Vancomycin Resistance in Methicillin-resistantFrontiers in immunology · 2023Article
- Impact of Growth Conditions onInternational journal of molecular sciences · 2022Article
- Evaluation ofPathogens (Basel, Switzerland) · 2022Article
- Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing.Microbiology spectrum · 2022Article
- Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (Journal of clinical medicine · 2021Review
- Determination of nasal carriage and skin colonization, antimicrobial susceptibility and genetic relatedness of Staphylococcus aureus isolated from patients with atopic dermatitis in Szczecin, Poland.BMC infectious diseases · 2021Article
- Nasal Methicillin-ResistantMicroorganisms · 2021Article
- Nasal Carriage of Methicillin-ResistantInternational journal of microbiology · 2021Article
- Design and Selection of Engineered Lytic Proteins WithFrontiers in microbiology · 2021Article
- Multidrug-Resistant Bacteria in the Community: An Update.Infectious disease clinics of North America · 2020Review
- Methicillin-resistant Staphylococcus aureus nasal colonization in cardiovascular surgery patients at a university hospital in Bogotá, ColombiaBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Phage Lytic Protein LysRODI Prevents Staphylococcal Mastitis in Mice.Frontiers in microbiology · 2020Article
- The effect of fennel essential oil andPostepy dermatologii i alergologii · 2019Article
- Intrawound Treatment for Prevention of Surgical Site Infections in Instrumented Spinal Surgery: A Systematic Comparative Effectiveness Review and Meta-Analysis.Global spine journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guidelines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S. aureus from the nose over a few weeks, but relapses are common within several months. There are only a few prospective randomized clinical trials that have been completed with sufficient patients, but those that have been reported suggest that clearance of S. aureus from the nose is beneficial in some patient groups for the reduction in the incidence of nosocomial infections. There is no convincing evidence that mupirocin treatment reduces the incidence of surgical site infection. New antibiotics are needed to decolonize the nose because bacterial resistance to mupirocin is rising, and so it will become less effective. Furthermore, a more bactericidal antibiotic than mupirocin is needed, on the grounds that it might reduce the relapse rate, and so clear the patient of MRSA for a longer period of time than mupirocin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.